While the biochemical characterization of neuropeptidedegrading enzymes in the nervous system has advanced rapidly in recent years, as evidenced by these proceedings, some major physiological questions regarding their functions remain unanswered. It is not clear whether these enzymes are concerned exclusively with inactivation, analogous to the breakdown of acetylcholine by acetylcholinesterase, or whether there is an important component of post-secretory processing (or biotransformation), involving the production of fragments with a different spectrum of regulatory activity or the formation of an active form from an inactive precursor. Neuropeptides are involved in signalling across a variety of junctions: these include the synaptic cleft in classical 'point-to-point' synapses, a diffuse pathway between the site of release from terminal varicosities and the receptors on adjacent cells in 'non-synaptic' transmission, and the humoral route in neuroendocrine regulation. The time course of peptide inactivation at such diverse target sites is probably very different and how this is controlled is not yet known. Clearly, the cellular and subcellular distribution of neuropeptide-degrading enzymes is of great importance, but the regulation of neuropeptide inactivation could also involve endogenous peptidase inhibitors. Although much of the current work focuses on peptidases presumed to be localized on the external surface of the synaptosomal plasma membrane, soluble peptidases present in the cytosol form the bulk of the central nervous system neuropeptide-degrading activity (at neutral pH) and the functional relationships of the membrane-bound, cytosolic and extracellular peptidases needs to be elucidated. No single experimental approach is likely to resolve such questions and progress will depend upon comparing the metabolism of neuropeptides by various preparations, Abbreviations used: CLIP, corticotropin-like intermediate lobe peptide; LH-RH, luteinizing hormone-releasing hormone (luliberin); TRH, thyrotrophin releasing hormone; CCK, cholecystokinin; h.p.l.c., high-performance liquid chromatography.
including incubated synaptosomes and other subcellular fractions, perifused tissue slices and purified enzymes, as well as studies in vivo.
Metabolism of neuropeptides by incubated synaptosomes
Synaptosomes were prepared from rat cerebral cortex or hypothalamus using a rapid procedure (Dodd el al., 1981) and incubated with various peptides (normally 20-60 PM) in Krebs-Ringer bicarbonate medium at 37°C. Incubations were terminated at various times up to 1 h by the addition of trifluoroacetic acid, and the peptide degradation products were identified by high performance liquid chromatography (h.p.1.c.) and amino-acid analysis, using methods described in detail elsewhere (McDermott et al., 1981 (McDermott et al., , 1982 (McDermott et al., , 1983a . Table 1 shows the primary cleavage points (where these have been identified) and the relative rates of metabolism of eleven peptides by nerve-endings isolated from rat cerebral cortex. One striking feature is the wide variation in the rate of degradation. Substance P was most rapidly broken down, in contrast with peptides such as CLIP and [Args]vasopressin which were metabolized at between 1-2% of the rate of substance P. A similar variation in the rate of metabolism for different peptides was observed with synaptosomes prepared from the hypothalamus. However, the 'specific activity' (i.e. nmol of peptide degraded/min per mg of protein) of hypothalamic synaptosomal peptidases against LH-RH, TRH and somatostatin was only 50% of that observed with the cortical preparations. This is surprising, in view of the much greater abundance of these peptides in the hypothalamus, but it may reflect the neuromodulatory role of these substances in the cortex, as opposed to the endocrine function of the same peptides stored in the neurosecretory terminals of the hypothalamus.
A feature of peptide metabolism observed with incubated synaptosomes is the relative importance of the hydrolysis of identical peptide bonds in different peptides. Thus, the major cleavage of TRH is at the pGlul-HisZ bond, in contrast with LH-RH in which an identical pGlul-HisZ bond is not significantly cleaved, or the pGluI-Leu* bond of neurotensin and the pClul-Glnz bond of bombesin which are similarly preserved. Although a pyroglutamyl aminopeptidase purified from brain hydrolyses the pGlul-HisZ Table 1 . Degradation of neuropeptides by synaptosomes from cerebral cortex: relative rates and primary cleavage points Neuropeptides were incubated with synaptosomes from rat cortex (0.2g of tissue equivalent/ml) suspended in KrebsRinger bicarbonate medium at 37"C, at peptide concentrations from 2 c 3 0 0 p~. Rates of degradation are calculated from time-course studies at 5, 15,30 and 60min, and are expressed relative (%)to the degradation of substance P which was most rapidly degraded (4.05 nmol/min per mg of protein). Peptide cleavage points were determined from the separation and identification of degradation products using reversed phase h.p.1.c. and amino acid analysis, as described in the text. Pro9-Gly10 Phe6-Phe' Leu4-GlyS, Val'*-Gly", His12-Leu13
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bond of both TRH and LH-RH (Bailer, 1983 ) the results from the present study suggest that, at synaptic terminals, this enzyme is important only for the metabolism of TRH. Post-ribosomal modifications of peptides, such as glycosylation, phosphorylation or sulphation, influence the rate of degradation by synaptosomal peptidases. Thus, both the sulphated and non-sulphated forms of cholecystokinin octapeptide were degraded by synaptosomes from rat cerebral cortex, the latter being removed much more rapidly, with half-lives under these experimental conditions of 84 and 34 min respectively (McDermott et al., 19836) . This increased stability of the sulphated form was even more marked on incubation with a purified human aminopeptidase, where breakdown was only 7% of the rate of the non-sulphated form (McDermott Pt al., 1983~) .
In some cases the internal cleavage of a peptide by synaptosomes is marked by the formai:ion of one relatively stable fragment while the other primary fragment is rapidly degraded further. LH-RH is cleaved at the Tyr5-Gly6 bond, giving rise to LH-RH-(1-5) and LH-RH-(&IO) peptides, with the C-terminal fragment being recovered in much smaller amounts because of its more rapid degradation (McDermott et al., 1983~) . A similar pattern is observed with neurotensin, cleavage at the Arg;8-Argg bond giving rise to the relatively stable neurotensin-(l-8)-peptide as the major product, with much smaller amounts of neurotensin-(9-1 3)-peptide being detected (McDermott et al., 1983~) . The relative stability of the N-termha1 fragments of LH-RH and neurotensin suggests that such metabolites could have independent biological activit,y. Such a view is supported by the finding that the: neurotensin-( 1-8)-fragment will antagonize behavioural effects of TRH administered directly into the periaqueductal grey region (Griffiths et al., 1982) .
Effect of enzyme inhibitors on the degrudation of peptides by synaptosomes
Most studies on neuropeptidase activity in brain have used crude soluble and particulate fractions, or synaptic membranes, or purified enzymes rather than intact synaptosomes. Several of the activities observed with synaptosomes in the present study could be due to enzymes which have been described previously using other preparations, but there are difficulties with such compairisons. For example, synaptosomes cleave LH-RH at the Tyr5-Gly6 bond and Camargo et al. (1982) have previously described a purified enzyme preparation (endo-oligopeptidase A) which hydrolyses the same bond. The enzyme described by these workers is preferentially active against LH-RH-( 1-9)-peptide whereas in our synaptosome experiments we observe that the LH-RH-(6-10)-fragment is much more abundant than LH-RH-(6-9), suggesting preferential cleavage of the intact molecule. This difference may simply reflect the fact that the (6-9)-fragment is relatively unprotected against further degradation in synaptosome suspensions. A further problem in interpreting data obtained with incubated synaptosomes is that several neuropeptide-degrading enzymes are active against a broad range of peptide bonds (see other papers in this Colloquium) and may also contain multi-catalytic sites. In an attempt to address this issue we have used inhibitors of three major enzymes thought to be involved in neuropeptide metabolism.
Thiorphan ( 1 0~~) was used to inhibit endopeptidase-24.11 (EC 3.4.24.11) which is active against several peptides including enkephalin, substance P, CCK and LH-RH (see Relton et al., 1983 , for references), bestatin ( 1 0~~) was used to inhibit aminopeptidase activity (Umezawa et al., 1976) and an antibody (Andrews et al., 1982) was used to inhibit the post-proline cleaving enzyme (E.C. 3.4.21.26) which has been implicated in the degradation of several neuropeptides (see Orlowski, 1983 , for review). Table 2 shows that in no case was the degradation of any of the five neuropeptides tested inhibited completely, although substantial inhibition of activity against substance P, somatostatin and CCK-8 was observed with antibody against prolyl endopeptidase, thiorphan and bestatin respectively, indicating the involvement of these peptidases with broad specificities in the synaptic metabolism of some neuropeptides. In comparison, these inhibitors were not effective against neurotensindegrading activity and attempts have been made to isolate and characterize the enzymes responsible for hydrolysis of this peptide.
Isolation and characterization of neurotensin-degrading enzyme
Both brain and pituitary contain a peptidase hydrolysing neurotensin at the Arg8-Arg9 bond and this peptidase has been isolated using ion exchange (TSK-545 DEAE) and gel filtration (TSK-G4000 SW) h.p. Table 2 . EJect of inhibitors on the degradation ofsome neuropeptides by rat cortical synaptosomes Peptides were incubated (concentration 30 p~) with synaptosomes in Krebs-Ringer bicarbonate medium for 15 and 60min. Degradation was measured using reverse phase h.p.1.c. separation with U.V. detection of the peptide peak.
Inhibition is expressed as % of the amount degraded in the absence of inhibitors. N.D., not determined, because there is no aminopeptidase susceptible residue in substance P, neurotensin or LH-RH, and no Pro residue in somatostatin or CCK. Abbreviation used: PPCE-Ab, antibody to prolyl endopeptidase. . The enzyme appears to be identical in both tissues. It has an M, of 65000-70000, and is a thiol-dependent metalloproteinase with a K,,, of 43 PM and a pH optimum of 7.5 (McDermott, 1984) . Under conditions in which 90% of added neurotensin was degraded the enzyme preparation was inactive against a wide range of neuropeptides including some containing Arg-Arg bonds or other dibasic residues. However, this enzyme did cleave the Arg6-Arg7 bond of dynorphin-( 1 -8)-fragment. Dynorphin-( 1 -13) was a potent inhibitor of the degradation of neurotensin but was only hydrolysed very slowly itself. Dynorphin-( 1-1 3) was used together with a range of inhibitors including phosphoramidon, captopril, bestatin and an antibody against prolyl endopeptidase, to determine which were effective against the breakdown of [-'H]neurotensin by superfused hypothalamic slices (McDermott et al., 1983d) . Neurotensin breakdown was 90% inhibited by dynorphin-( 1-1 3)-peptide but was inhibited to a lesser extent (23%) by captopril, a potent inhibitor of angiotensin converting enzyme (EC 3.4.15.1) which releases the C-terminal Ile-Leu dipeptide from neurotensin (Erdos & Skidgel, 1985) . Phosphoramidon, bestatin and the antibody to prolyl endopeptidase had no significant effect. The results suggest that this Arg8-Arg9-cleaving endopeptidase is the major neurotensindegrading enzyme in the brain, being highly active in both the synaptosome and superfused tissue slice preparations. Recently we have found that a purified preparation of this activity is equally active against the Pro7-Phe8 bond of angiotensin and Phe5-Ser6 bonds of bradykinin, and it remains to be determined whether these activities are due to separate catalytic sites. Activity against the Phe5-Ser6 bond of bradykinin has been previously ascribed to endo-oligopeptidase A, which also cleaves LH-RH-( I-9)-peptide at the TyrS-Glyh bond (Camargo et at., 1973, 1982) . Under conditions where neurotensin was extensively degraded, the ArgH-Argy-cleaving endopeptidase was not active against intact LH-RH although activity against the fragment (1-9)
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has not yet been tested.
Presence of peptidases in pituitary colloid
The brain and pituitary gland contain similar membrane and cytosol peptidases which degrade neuropeptides, and this aspect has been reviewed extensively elsewhere (Grifiths & McDermott, 1983 ). Recently we have drawn attention to the presence of butyrylcholinesterase and various peptidases in pituitary colloid, a proteinaceous secretion found in the hypophysial cleft and other extracellular compartments of the pituitary gland, and which appears after a variety of endocrine manipulations including oestrogen treatment, salt-loading, thyroidectomy or adrenalectomy (Das et al., 1982) . Amongst various enzyme activities which have been detected in pituitary colloid are several similar to those observed with synaptosome preparations, including activity against the Arg8-Arg9 bond of neurotensin and the Tyrs-Gly6 bond of LH-RH. Furthermore, colloid also contains an enzyme which removes the C-terminal Phe?? residue from CLIP. Des-Phe'VLIP is a major product of the processing of the precursor pro-opiomelanocortin in the brain (Smith et al., 1982) (Chubb & Hodgson, 1982) , will also hydrolyse substance P (Chubb et at., 1980). Thus, it is possible that some peptidases may have multiple roles, being active in intracellular compartments, at the plasma membrane and in extracellular fluid. The mechanisms and significance of peptidase transport between these various compartments remain to be established.
